Agency introduces new method to check fake drugs
The National Food and Drug Administration and Control Agency
(NAFDAC) will today, at its Lagos office, introduce a solution meant to be the
silver bullet against the monstrous fake drug business in the country.
The data collected from a three-month trial of the Mobile
Authentication Service (MAS), an SMS-based solution implemented by Sproxil Inc,
will also be discussed at the meeting with drugs manufacturers and retailers.
The innovative technology has been described as most suitable
for checkmating fake drugs in Sub-Saharan Africa, where the counterfeit drugs
business is estimated to be worth about $75 billion, because it utilises the
ubiquitous mobile phone platform.
The model is as simple as a consumer walking into a
pharmaceutical store to buy drugs, which would have a scratch panel. The
consumer scratches the panel and sends the code on it to a well-advertised
number through SMS. A confirmation message will be sent back confirming the genuineness
or otherwise of the drug. If the drug is counterfeited, the consumer is
expected to inform NAFDAC.
Anti-counterfeit
officials
This model, which will also be effective against all forms of
counterfeited and sub-standard products, will turn consumers to an independent
army of “anti-counterfeit officials,” one as big as the entire Nigerian
populace, if implemented efficiently.
The document, which was exclusively obtained by NEXT, was
prepared by a national committee inaugurated by Paul Orhii, NAFDAC’s Director
General, in June 2009.
The committee consisted of representatives of the
Pharmaceutical Manufacturers of Nigeria (PMG-MAN), Nigerian Representatives of
Overseas Pharmaceutical Manufacturers (NIROPHARM), and mPedigree, the company
marketing the product.
The committee submitted its report, Deployment of National
Electronic Anti-Counterfeiting Platform for Regulated Products in Nigeria, in
September 2009. Thereafter, Biofem agreed to use its “highly counterfeited”
product, glucophage, as a “guinea pig” and in February, NAFDAC announced a
trial project, to be implemented by Sproxil.
The feasibility of the guideline document requires several
partnership agreement and understanding among several components of the design
including telecommunication companies, drug manufacturing companies,
Information Technology Company, and NAFDAC.
However, Biofem-Spiroxil partnership has, within a shorter
period, produced an implementation platform for the technology and the trial
has received positive feedback from industry stakeholders.
For a detailed report on
this, read NEXTonSunday